Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | TOP2A | P11388 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470822 | 0.85 | KDM4E (0.50) | MAOATOP2ACYP3A4KDM4EHPGD | |
| SCHEMBL3397900 | 0.85 | TOP2A (0.41) | MAOATOP2AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29440785 | 0.84 | AKR1C3 (0.54) | MAOATOP2AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL61277 | 0.84 | AKR1C3 (0.54) | MAOATOP2AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29440787 | 0.84 | AKR1C3 (0.54) | MAOATOP2AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL311429 | 0.80 | MAOA (0.46) | MAOAEGFRATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5842306 | 0.77 | KDM4E (0.57) | MAOATOP2AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6759892 | 0.74 | HPGD (0.41) | MAOAKDM4EHPGDMEN1MAPT | |
| SCHEMBL914704 | 0.73 | C1R (0.68) | TOP2AKDM4EHPGDMEN1MAPT | |
| SCHEMBL30025189 | 0.73 | C1R (0.68) | TOP2AKDM4EHPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074815-B2 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2006-07-11 | — | — | US | disclosed |
| US-20050080120-A1 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2005-04-14 | — | — | US | disclosed |
| EP-1443924-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003039541-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080120-A1 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | PAH, P4HA1, CYP27B1 | MAOA 970/4885TOP2A 2003/4885EGFR 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.